Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | GAA | P10253 | 5/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.44 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2697621 | 0.87 | ALDH1A1 (0.52) | DHODHMAPTGAAPTGDR2ALDH1A1 | |
| SCHEMBL2697298 | 0.84 | DHODH (0.48) | DHODHMAPTGAAPTGDR2ALDH1A1 | |
| SCHEMBL206039 | 0.84 | DHODH (0.59) | DHODHMAPTGAAALDH1A1MEN1 | |
| SCHEMBL207159 | 0.84 | DHODH (0.48) | DHODHMAPTGAAPTGDR2ALDH1A1 | |
| SCHEMBL207114 | 0.82 | PTPRC (0.49) | DHODHMAPTGAAPTGDR2ALDH1A1 | |
| SCHEMBL206829 | 0.82 | PTPRC (0.49) | DHODHMAPTGAAPTGDR2ALDH1A1 | |
| SCHEMBL2698355 | 0.80 | PPARD (0.51) | DHODHMAPTGAAPTGDR2ALDH1A1 | |
| SCHEMBL205173 | 0.78 | ALDH1A1 (0.59) | MAPTPTGDR2ALDH1A1MEN1KMT2A | |
| SCHEMBL206635 | 0.77 | PTGS2 (0.58) | MAPTPTGDR2ALDH1A1HSD17B10MAPK1 | |
| SCHEMBL18904197 | 0.76 | MAPT (0.52) | DHODHMAPTGAAPTGDR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004711-A1 | Thiazole compounds and methods of use | PIGS, CPT1A, SLC10A1 | DHODH 1219/4885MAPT 2207/4885GAA 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.